Antigen presentation safeguards the integrity of the hematopoietic stem cell pool

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Pablo Hernández-Malmierca - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ), Heidelberg University  (First author)
  • Dominik Vonficht - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ), Heidelberg University  (Author)
  • Alexandra Schnell - , Harvard University, Broad Institute of Harvard University and MIT (Author)
  • Hannah J. Uckelmann - , Dana-Farber Cancer Institute, Harvard University (Author)
  • Alina Bollhagen - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ) (Author)
  • Mohamed A.A. Mahmoud - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ) (Author)
  • Sophie Luise Landua - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ) (Author)
  • Elise van der Salm - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ) (Author)
  • Christine L. Trautmann - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ) (Author)
  • Simon Raffel - , Heidelberg University  (Author)
  • Florian Grünschläger - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ), Heidelberg University  (Author)
  • Raphael Lutz - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ), Heidelberg University  (Author)
  • Michael Ghosh - , University of Tübingen (Author)
  • Simon Renders - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ), Heidelberg University  (Author)
  • Nádia Correia - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ) (Author)
  • Elisa Donato - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ) (Author)
  • Karin O. Dixon - , Harvard University, Broad Institute of Harvard University and MIT (Author)
  • Christoph Hirche - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ) (Author)
  • Carolin Andresen - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ), Heidelberg University  (Author)
  • Claudia Robens - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ) (Author)
  • Paula S. Werner - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ) (Author)
  • Tobias Boch - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ), Heidelberg University  (Author)
  • David Eisel - , German Cancer Research Center (DKFZ) (Author)
  • Wolfram Osen - , German Cancer Research Center (DKFZ) (Author)
  • Franziska Pilz - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ) (Author)
  • Adriana Przybylla - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ) (Author)
  • Corinna Klein - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ) (Author)
  • Frank Buchholz - , University Cancer Centre Dresden, Medical Systems Biology, University Cancer Centre Dresden, National Center for Tumor Diseases Dresden (Author)
  • Michael D. Milsom - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ) (Author)
  • Marieke A.G. Essers - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ) (Author)
  • Stefan B. Eichmüller - , German Cancer Research Center (DKFZ) (Author)
  • Wolf Karsten Hofmann - , Heidelberg University  (Author)
  • Daniel Nowak - , Heidelberg University  (Author)
  • Daniel Hübschmann - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ) (Author)
  • Michael Hundemer - , Heidelberg University  (Author)
  • Christian Thiede - , Department of Internal Medicine I, German Cancer Consortium (DKTK) Core Center Heidelberg (Author)
  • Lars Bullinger - , German Cancer Research Center (DKFZ), Charité – Universitätsmedizin Berlin (Author)
  • Carsten Müller-Tidow - , Heidelberg University  (Author)
  • Scott A. Armstrong - , Dana-Farber Cancer Institute, Harvard University (Author)
  • Andreas Trumpp - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ) (Author)
  • Vijay K. Kuchroo - , Harvard University, Broad Institute of Harvard University and MIT (Author)
  • Simon Haas - , Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), German Cancer Research Center (DKFZ), Charité – Universitätsmedizin Berlin, Max Delbrück Center for Molecular Medicine (MDC) (Last author)

Abstract

Hematopoietic stem and progenitor cells (HSPCs) are responsible for the production of blood and immune cells. Throughout life, HSPCs acquire oncogenic aberrations that can cause hematological cancers. Although molecular programs maintaining stem cell integrity have been identified, safety mechanisms eliminating malignant HSPCs from the stem cell pool remain poorly characterized. Here, we show that HSPCs constitutively present antigens via major histocompatibility complex class II. The presentation of immunogenic antigens, as occurring during malignant transformation, triggers bidirectional interactions between HSPCs and antigen-specific CD4+ T cells, causing stem cell proliferation, differentiation, and specific exhaustion of aberrant HSPCs. This immunosurveillance mechanism effectively eliminates transformed HSPCs from the hematopoietic system, thereby preventing leukemia onset. Together, our data reveal a bidirectional interaction between HSPCs and CD4+ T cells, demonstrating that HSPCs are not only passive receivers of immunological signals but also actively engage in adaptive immune responses to safeguard the integrity of the stem cell pool.

Details

Original languageEnglish
Pages (from-to)760-775.e10
JournalCell Stem Cell
Volume29
Issue number5
Publication statusPublished - 5 May 2022
Peer-reviewedYes

External IDs

PubMed 35523139

Keywords

Sustainable Development Goals

Keywords

  • acute myeloid leukemia, antigen presentation, CD4 T cells, hematopoietic stem cells, immune regulation, immunosurveillance, leukemia

Library keywords